Overview

Phase II BGG492 Capsule Extension for Partial Epilepsy

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This long-term extension study will assess the safety, tolerability and efficacy of BGG492 as adjunctive treatment in patients with partial onset seizures.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals